Risheek Kaul

Risheek Kaul

Auto-generated profile, based on publicly available information

Risheek Kaul

Leon H. Charney Division of Cardiology. New York University Langone Health. New York, NY, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in ASAIO Journal
Verified
Journal Article
Closed access
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
RKRisheek Kaul
Risheek Kaul
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
SRSagar Ranka
Sagar Ranka
RDRyan T. Demmer
Ryan T. Demmer
PCPaolo C. Colombo
Paolo C. Colombo
Left ventricular assist device (LVAD) implantation in patients with advanced heart failure due to hypertrophic or restrictive cardiomyopathy (HCM/RCM) presents technical and physiologic challenges. We conducted a systematic review of observational studies to evaluate the utilization and clinical outcomes associated with LVAD implantation in patients with HCM/RCM and compared these to patients with dilated or ischemic cardiomyopathy (DCM/ICM). We searched MEDLINE, EMBASE, and Scopus from inception through May 2019 and included appropriate studies describing the use of an LVAD in patients with HCM/RCM. We identified six studies with a total of 2,766 patients with HCM/RCM and advanced heart failure, among whom 338 patients (12.2%) underwent LVAD implantation. In patients listed for transplant, the rate of LVAD implantation was significantly lower in patients with HCM/RCM compared to that in patients with DCM/ICM (4.4% vs. 18.2%, p < 0.001). Adverse clinical outcomes were significantly higher in HCM/RCM than in DCM/ICM, including operative/short-term mortality (14.0% vs. 9.0%), right ventricular failure (50.0% vs. 21.0%), infection (15.5% vs. 11.2%), bleeding (40.2% vs. 12.5%), renal failure (15.0% vs. 5.1%), stroke (5.0% vs. 2.4%), and arrhythmias (18.0% vs. 7.7%) (all p values <0.001).

20 September 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
RKRisheek Kaul
Risheek Kaul
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
AGAkshay Goel
Akshay Goel
AMAaqib Malik
Aaqib Malik
DBDhrubajyoti Bandyopadhyay
Dhrubajyoti Bandyopadhyay
JPJulio A. Panza
Julio A. Panza

16 August 2021 in Heart
Verified
Journal Article
Closed access
PDF file
SMSae Morita
Sae Morita
AMAaqib H Malik
Aaqib H Malik
TKToshiki Kuno
Toshiki Kuno
TATomo Ando
Tomo Ando
RKRisheek Kaul
Risheek Kaul
Alexandros BriasoulisAlexandros Briasoulis
Alexandros Briasoulis
Objective Percutaneous left atrial appendage occlusion (LAAO) is an alternative strategy for prevention of thromboembolic events in patients with atrial fibrillation and unsuitable for long-term oral anticoagulation. The study aimed to evaluate the causes and timing of readmissions within 6 months following percutaneous LAAO in a real-world setting. Methods We conducted a retrospective cohort study of percutaneous LAAO performed in the USA between January and June of 2016–2018 using the Nationwide Readmissions Database. Results Overall, 12 446 patients who underwent LAAO were included in the analyses and 3477 patients (28%) were readmitted within 6 months following the interventions. Readmitted patients were more often women (p=0.001). The index hospitalisation was characterised by longer duration of hospital stay (p<0.001) and complicated with acute kidney injury (p<0.001) among readmitted patients compared with those without readmissions. Readmissions within 6 months following the index intervention were mainly due to heart failure (13%) and gastrointestinal bleeding (12%). Characteristics associated with readmissions due to heart failure included previously known heart failure (HR 2.39; 95% CI 1.70 to 3.37), valvular heart disease (HR 1.39; 95% CI 1.05 to 1.84) and chronic kidney disease (HR 1.42; 95% CI 1.03 to 1.94). Readmissions due to gastrointestinal bleeding were associated with diabetes mellitus (HR 1.78; 95% CI 1.25 to 2.53), chronic kidney disease (HR 1.86; 95% CI 1.23 to 2.81) and previous anaemia (HR 2.41; 95% CI 1.54 to 3.77). Conclusions After percutaneous LAAO, over a quarter of the patients in the USA required rehospitalisation within 6 months, mainly due to heart failure and gastrointestinal bleeding.

22 January 2024 in Heart Rhythm
Verified
Journal Article
Closed access
RKRisheek Kaul
Risheek Kaul
FYFelix Yang
Felix Yang
MSMohamed Shokr
Mohamed Shokr
LJLior Jankelson
Lior Jankelson
RKRobert J. Knotts
Robert J. Knotts
CBChirag R. Barbhaiya
Chirag R. Barbhaiya